Koichi Kameda
Biographic Data
| ID | 879448 |
|---|---|
| NAME | Koichi Kameda |
| GIVEN NAMES | Koichi |
| FAMILY NAME | Kameda |
| SIGNATURE | KAMEDA K |
| AFFILIATIONS | Centre Population et Développement |
| ORCID | 0000-0003-1337-6501 |
| VERIFIED | Yes |
| TOTAL WORKS | 10 |
| TOTAL CITATIONS | 18 |
| AUTHOR COUNT | 10 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2014 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 3 |
Taking medicines out of the market
Rumo à equidade em saúde
Towards equity in health
O artigo discute a meta do Ministério da Saúde de produzir localmente 70% dos insumos para o Sistema Único de Saúde (SUS). A iniciativa visa reduzir a dependência externa, uma vulnerabilidade exposta durante a pandemia de COVID-19. Os autores destacam desafios como: Altos preços de medicamentos devido a patentes; A necessidade de desenvolver produtos para doenças negligenciadas, que não atraem o setor privado; A falta de produção nacional de insu…
Imperfect diagnosis
When the Zika virus burst onto the international scene in the second half of 2015, the development of diagnostic tools was seen as an urgent global health priority. Diagnostic capacity was restricted to a small number of reference laboratories, and none of the few available molecular or serological tests had been validated for extensive use in an outbreak setting. In the early weeks of the crisis, key funders stepped in to accelerate research and…
Testing Covid-19 in Brazil
Since the first recorded case of COVID-19 on February 26, 2020, Brazil has seen an exponential growth in the number of cases and deaths. The national testing approach has been insufficient to correctly use this tool in the support of containing the epidemic in the country. In this communication, we discuss efforts and challenges to scale-up COVID-19 testing at the Brazilian Unified National Health System (SUS). This communication presents the ini…
Molecular Sovereignty
This article interrogates the relationship between the development of national diagnostic technologies and the exercise of sovereignty, by analysing a Brazilian project to produce a nucleic acid test (NAT) for the country's blood screening programme. The concept of 'molecular sovereignty' is proposed to demonstrate that exercising sovereignty demands not only technological resources but also a sufficiently powerful and national imaginary to suppo…
The Introduction of Nucleic Acid Tests (NAT) for Blood Screening in the Brazilian Public Healthcare System
Testing the Nation
Tester la Nation : politiques de santé et l'innovation technologique pour le diagnostic des maladies infectieuses au Brésil Le diagnostic in vitro (DIV) est un segment des biotechnologies de santé pour lequel les principaux acteurs se situent dans les pays développés. Parallèlement, le paysage actuel a contraint les compagnies multinationales à transformer leur modèle économique, tout en obligeant les pays non-occidentaux à devenir de nouveaux ma…
A incorporação do teste diagnóstico baseado na amplificação de ácidos nucleicos (NAT) para triagem de sangue no SUS
Os testes de ácidos nucleicos (NAT) são ferramentas complementares aos testes sorológicos para controle da transmissão de doenças infecciosas por meio de produtos obtidos a partir do sangue. Em 2002, um decreto do Ministério da Saúde tornou obrigatória a realização do NAT por todos os bancos de sangue, medida dificultada por razões como os custos necessários para a sua implantação. Como estratégia para a sua incorporação nos bancos de sangue liga…
Needs‐Driven Versus Market‐Driven Pharmaceutical Innovation
The prevailing model for encouraging innovation based on patents and market‐oriented raises at least two economic and ethical issues: it imposes barriers on individuals and developing countries governments' access to medicines by defining prices that do not match their income, and the unavailability of new or appropriate products to address the health problems of these populations. In the last decade, this scenario has undergone some changes due …
Imperfect diagnosis
When the Zika virus burst onto the international scene in the second half of 2015, the development of diagnostic tools was seen as an urgent global health priority. Diagnostic capacity was restricted to a small number of reference laboratories, and none of the few available molecular or serological tests had been validated for extensive use in an outbreak setting. In the early weeks of the crisis, key funders stepped in to accelerate research and…
Testing Covid-19 in Brazil
Since the first recorded case of COVID-19 on February 26, 2020, Brazil has seen an exponential growth in the number of cases and deaths. The national testing approach has been insufficient to correctly use this tool in the support of containing the epidemic in the country. In this communication, we discuss efforts and challenges to scale-up COVID-19 testing at the Brazilian Unified National Health System (SUS). This communication presents the ini…
Molecular Sovereignty
This article interrogates the relationship between the development of national diagnostic technologies and the exercise of sovereignty, by analysing a Brazilian project to produce a nucleic acid test (NAT) for the country's blood screening programme. The concept of 'molecular sovereignty' is proposed to demonstrate that exercising sovereignty demands not only technological resources but also a sufficiently powerful and national imaginary to suppo…
A incorporação do teste diagnóstico baseado na amplificação de ácidos nucleicos (NAT) para triagem de sangue no SUS
Os testes de ácidos nucleicos (NAT) são ferramentas complementares aos testes sorológicos para controle da transmissão de doenças infecciosas por meio de produtos obtidos a partir do sangue. Em 2002, um decreto do Ministério da Saúde tornou obrigatória a realização do NAT por todos os bancos de sangue, medida dificultada por razões como os custos necessários para a sua implantação. Como estratégia para a sua incorporação nos bancos de sangue liga…
Needs‐Driven Versus Market‐Driven Pharmaceutical Innovation
The prevailing model for encouraging innovation based on patents and market‐oriented raises at least two economic and ethical issues: it imposes barriers on individuals and developing countries governments' access to medicines by defining prices that do not match their income, and the unavailability of new or appropriate products to address the health problems of these populations. In the last decade, this scenario has undergone some changes due …
A incorporação do teste diagnóstico baseado na amplificação de ácidos nucleicos (NAT) para triagem de sangue no SUS
Os testes de ácidos nucleicos (NAT) são ferramentas complementares aos testes sorológicos para controle da transmissão de doenças infecciosas por meio de produtos obtidos a partir do sangue. Em 2002, um decreto do Ministério da Saúde tornou obrigatória a realização do NAT por todos os bancos de sangue, medida dificultada por razões como os custos necessários para a sua implantação. Como estratégia para a sua incorporação nos bancos de sangue liga…
The Introduction of Nucleic Acid Tests (NAT) for Blood Screening in the Brazilian Public Healthcare System
Testing the Nation
Tester la Nation : politiques de santé et l'innovation technologique pour le diagnostic des maladies infectieuses au Brésil Le diagnostic in vitro (DIV) est un segment des biotechnologies de santé pour lequel les principaux acteurs se situent dans les pays développés. Parallèlement, le paysage actuel a contraint les compagnies multinationales à transformer leur modèle économique, tout en obligeant les pays non-occidentaux à devenir de nouveaux ma…
Imperfect diagnosis
When the Zika virus burst onto the international scene in the second half of 2015, the development of diagnostic tools was seen as an urgent global health priority. Diagnostic capacity was restricted to a small number of reference laboratories, and none of the few available molecular or serological tests had been validated for extensive use in an outbreak setting. In the early weeks of the crisis, key funders stepped in to accelerate research and…
Testing Covid-19 in Brazil
Since the first recorded case of COVID-19 on February 26, 2020, Brazil has seen an exponential growth in the number of cases and deaths. The national testing approach has been insufficient to correctly use this tool in the support of containing the epidemic in the country. In this communication, we discuss efforts and challenges to scale-up COVID-19 testing at the Brazilian Unified National Health System (SUS). This communication presents the ini…
Molecular Sovereignty
This article interrogates the relationship between the development of national diagnostic technologies and the exercise of sovereignty, by analysing a Brazilian project to produce a nucleic acid test (NAT) for the country's blood screening programme. The concept of 'molecular sovereignty' is proposed to demonstrate that exercising sovereignty demands not only technological resources but also a sufficiently powerful and national imaginary to suppo…
Rumo à equidade em saúde
Towards equity in health
O artigo discute a meta do Ministério da Saúde de produzir localmente 70% dos insumos para o Sistema Único de Saúde (SUS). A iniciativa visa reduzir a dependência externa, uma vulnerabilidade exposta durante a pandemia de COVID-19. Os autores destacam desafios como: Altos preços de medicamentos devido a patentes; A necessidade de desenvolver produtos para doenças negligenciadas, que não atraem o setor privado; A falta de produção nacional de insu…
Taking medicines out of the market
Political science (8 works) · Economic growth (6 works) · Economics (6 works) · Business (5 works) · Health care (5 works) · Biotechnology and Related Fields (4 works) · Geography (4 works) · Medicine (4 works) · Computer Science (3 works) · Law (3 works)